Skip to main content

ANAPTYSBIO INC

For the period ended Dec 31, 2024. Filed Feb 27, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 27, 2025

ANAB$48.38+0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Financial Statements Consolidated Balance Sheets

(in thousands, except par value)

December 31, 2024December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents$123,080$35,965
Receivables from collaborative partners40,7656,851
Short-term investments262,293354,939
Prepaid expenses and other current assets5,7389,080
Total current assets431,876406,835
Property and equipment, net1,8492,098
Operating lease right-of-use assets14,38316,174
Long-term investments35,47027,026
Other long-term assets256256
Total assets$483,834$452,389
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$4,002$4,698
Accrued expenses39,50130,967
Current portion of operating lease liability1,9251,777
Total current liabilities45,42837,442
Liability related to sale of future royalties353,426310,807
Operating lease liability, net of current portion14,11216,037
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at December 31, 2024 and December 31, 2023, respectively——
Common stock, $0.001 par value, 500,000 shares authorized, 30,473 shares and 26,597 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively3027
Additional paid in capital829,860702,969
Accumulated other comprehensive gain (loss)305(797)
Accumulated deficit(759,327)(614,096)
Total stockholders’ equity70,86888,103
Total liabilities and stockholders’ equity$483,834$452,389
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.